[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595433":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":24,"responsibleParty":55,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":18,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":27,"whyStopped":18,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Polypill","EXPERIMENTAL","The polypill combines DAPT and a high intensity statin: (a) aspirin 81 mg, (b) rosuvastatin (40 or 10 mg) and (c) prasugrel 10 mg or clopidogrel 75 mg.",[13],"Combination Product: Polypill",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual care","NO_INTERVENTION","Participants in the usual care arm will be prescribed DAPT and statins as standard therapy in individual pills.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"COMBINATION_PRODUCT","The polypill is an inert capsule designed to combine multiple individual medications into a convenient, once-daily pill. In this case it will include DAPT and a statin.",[9],[25,45],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Baylor Scott and White Health System","RECRUITING","Dallas","Texas","75093","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-96.80667,32.78306,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":43,"phoneExt":18,"email":44},"Neil Keshvani, MD","CONTACT","469-814-3278","neil.keshvani@bswhealth.org",{"facility":5,"status":27,"city":28,"state":29,"zip":46,"country":31,"countryCode":32,"cosmosGeoPoint":47,"geoPoint":49,"contacts":50},"75209",{"type":34,"coordinates":48},[36,37],{"lat":37,"lon":36},[51],{"name":52,"role":42,"phone":53,"phoneExt":18,"email":54},"Ambarish Pandey, MD","214-645-9868","ambarish.pandey@utsouthwestern.edu",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Ambarish Pandey","Associate Professor",[60],{"name":61,"class":62},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100595433","phase-2-a-polypill-for-acute-coronary-syndrome-100595433",false,"NCT07032389","A Polypill for Acute Coronary Syndrome","Polypill Strategy for the Treatment of Patients After Acute Coronary Syndromes - A Multicenter Randomized Controlled Trial","PolyACS","Inclusion Criteria:\n\n* Age ≥ 18\n* Hospitalization for acute coronary syndrome with percutaneous coronary intervention\n* Discharged on aspirin, prasugrel or clopidogrel, and a high-intensity statin\n\nExclusion Criteria:\n\n* Current need for systemic anticoagulation\n* Contraindication to receive any components of the polypill\n* History of allergic reaction or intolerance to aspirin, prasugrel or clopidogrel, or rosuvastatin\n* Comorbidities that might be expected to limit lifespan within the 12-month study period\n* Increased risk of bleeding or planned urgent surgery that would necessitate use of DAPT for \\\u003C 12 months\n* Inability to provide written informed consent\n* Pregnancy","ALL","18 Years",{"count":74,"type":75},1000,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The current study aims to investigate whether combining the standard medications prescribed after acute coronary syndrome (ACS)-aspirin, P2Y12 inhibitors, and statins-into a single polypill can improve outcomes following an ACS event. Although these therapies are effective, gaps in adherence and uptake significantly contribute to risk or adverse events in the post-ACS period. This study is designed as a pragmatic, multi-center, randomized trial to assess the feasibility and effectiveness of a polypill-based strategy for treatment of ACS.",[81],"Acute Coronary Syndrome",[81,9,83],"Adherence","2026-07-08",{"date":86,"type":87},"2026-07-10","ACTUAL",{"date":89,"type":87},"2025-12-05",{"date":91,"type":75},"2030-07-31",{"name":5,"class":6},2]